

Familial Breast Cancer Advisory Committee Interests Register

Register last updated: 05/01/26

All interests have been signed off by the Chair and the NICE Developer Lead

| Name | Role on the committee | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|----------------|--------------------------|---|--|----------------|-------------------|-----------------|---|
| Alison Cameron | Committee member - Chair | Direct-financial | Consultant Clinical Oncologist, University Bristol and Weston NHS Foundation Trust. | 06/07 | 03/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Alison Cameron | Committee member - Chair | Direct, non-financial professional and personal | I am a member of the Royal College of Radiologists Society Training Board and curriculum committee. This role is unpaid. This is not directly related to the guideline, but we may have teaching sessions related to this content. | 2021 | 03/25 | Ongoing | Non-specific Declare and participate |
| Alison Cameron | Committee member - Chair | Direct, non-financial professional and personal | I am a Royal College of Radiologists e-learning lead for Clinical Oncology. This role is unpaid. This is not directly related to the guideline, but we may have teaching sessions related to this content. | 12/24 | 03/25 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|-------------------------|--|---|--|-------|-------|---------|---|
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct-financial | Breast Advanced Nurse Practitioner, Royal Liverpool Hospital. | 08/14 | 05/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Nurse member on the education and training committee for the Association of Breast Surgery. This role is unpaid. | 05/25 | 05/25 | Ongoing | Non-specific Declare and participate |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Davies-Crowley K, Brooks R. Expanding role of the breast advanced nurse practitioner: mainstream pathway for genetic testing . Br J Nurs. 2025 May 22;34(10):S26-S30. doi: 10.12968/bjon.2024.0474. PMID: 40396950. | 05/25 | 05/25 | 05/25 | Non-specific Declare and participate |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Potter S, Fairhurst K, Cowan K, Vincent S, Lewis I, Cutress RI, Stobart H, Fairbrother P, Turner S, Davies-Crowley K, Jeevan R, Rattay T, O'Connell R, Bundred N, McIntosh SA. Identifying research priorities in breast cancer surgery: a UK priority setting | 11/22 | 05/25 | 11/22 | Non-specific Declare and participate |

| | | | | | | | |
|-------------------------|--|---|--|-------|-------|-------|---|
| | | | partnership with the James Lind Alliance . Breast Cancer Res Treat. 2023 Jan;197(1):39-49. doi: 10.1007/s10549-022-06756-4. Epub 2022 Nov 1. PMID: 36319906; PMCID: PMC9628302. | | | | |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Service evaluation of newly established breast mainstream genetic R208 panel testing undertaken at liverpool university hospital foundation trust (LUHFT) Davies-Crowley, Kayleigh, Brooks, Rebecca European Journal of Surgical Oncology, Volume 51, 109818 DOI: 10.1016/j.ejso.2025.109818 | 05/25 | 05/25 | 05/25 | Non-specific Declare and participate |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Outcomes of advice and guidance referrals to a large breast surgery service Lennon, Hannah et al. | 05/24 | 05/25 | 05/24 | Non-specific Declare and participate |

| | | | | | | | |
|-----------------|---|---|--|-------|-------|---------|---|
| | | | May 2024European Journal of Surgical Oncology 50:108134 DOI: 10.1016/j.ejso.2024.10813 4 | | | | |
| Rachael Griffin | Co-opted member – Lay member | Direct-financial | I work for a company (Jazz Pharmaceuticals) that runs clinical trials. Some in breast cancer as they are trials for the drug Zanidatamab. However, I am not involved in the trials themselves. I work in Clinical Outsourcing - overseeing our 3rd party suppliers. | 04/22 | 07/25 | Ongoing | Non-specific Declare and participate |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | UK Cancer Genetics Group (UKCGG): Chair of UKCGG (Term 2021- 2024) - retiring Chair May 2024-2025. Led on improving access and consistency of care of patients with rare inherited predisposition syndrome. I received no payment or honourarium for this role | 01/23 | 03/25 | 05/25 | Non-specific Declare and participate |

| | | | | | | | |
|--------------|--|--|---|-------|-------|-------|--|
| | | | other than travel expenses. | | | | |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal and indirect-financial | <p>Co-investigator on “CanGene-CanVar” a 5-year £4.3 million Cancer Research UK catalyst award-funded programme. (Sept 2019 –March 2025) as part of Work Package 3 :Translation and implementation of Clinical Guidelines.</p> <p>Research monies went to my institution.</p> <p>During this time I have co-authored and published a number of papers on recommended clinical management of individuals with inherited cancer predisposition, including those with a predisposition to breast cancer. Those relevant to breast cancer are included below.</p> | 09/19 | 03/25 | 03/25 | Specific Declare and participate Individual papers assessed below. |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | <p>Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the</p> | 01/25 | 03/25 | 01/25 | Specific Declare and participate |

| | | | | | | | |
|--------------|--|---|--|-------|-------|-------|--|
| | | | American College of Medical Genetics and Genomics (ACMG) . Pal T, Schon KR, Astiazaran-Symonds E, Balmaña J, Foulkes WD, James P, Klugman S, Livinski AA, Mak JS, Ngeow J, Voian N, Wick MJ, Hanson H, Stewart DR, Tischkowitz M; ACMG Professional Practice and Guidelines Committee. Genet Med. 2025 Jan;27(1):101243. doi: 10.1016/j.gim.2024.101243. PMID: 39636577 | | | | Despite being specific to the topic under consideration this paper would not be included in the evidence base. |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing . Rowlands CF, Allen S, Balmaña J, Domchek SM, Evans DG, Hanson H, Hoogerbrugge N, James PA, Nathanson KL, Robson M, Tischkowitz M, Foulkes WD, Turnbull C. Ann Oncol. 2024 Oct;35(10):892-901. doi: 10.1016/j.annonc.2024.07.244. PMID: 38986768. | 10/24 | 03/25 | 10/24 | Non-specific Declare and participate |

| | | | | | | | |
|--------------|---|---|---|-------|-------|-------|--|
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Digital innovation for cancer risk assessment allows large-scale service redevelopment of regional cancer genetics service delivery. Youngs A, Forman A, Elms M, Kohut K, Hlaing MT, Short J, Hanson H, Snape K. Fam Cancer. 2024 Nov;23(4):591-598. doi: 10.1007/s10689-024-00407-x. PMID: 38954285; | 11/24 | 03/25 | 11/24 | Non-specific Declare and participate |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice. Tsoulaki O, Tischkowitz M, Antoniou AC, Musgrave H, Rea G, Gandhi A, Cox K, Irvine T, Holcombe S, Eccles D, Turnbull C, Cutress R; Meeting Attendees; Archer S, Hanson H.. Br J Cancer. 2024 Jun;130(12):2027-2036. doi: 10.1038/s41416-024-02733-4. PMID: 38834743 | 06/24 | 03/25 | 06/24 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|---|---|---|-------|-------|-------|--|
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling study. Huntley C, Torr B, Kavanaugh G, George A, Hanson H, Snape K, Broggio J, Glasgow L, Tischkowitz M, Evans DG, Antoniou AC, Turnbull C. Br J Gen Pract. 2024 Aug 29;74(746):e610-e618. doi: 10.3399/BJGP.2023.0327. PMID: 38724186 | 08/24 | 03/25 | 08/24 | Non-specific Declare and participate |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, Logan P, Robinson R, Sheils K, Wolstenholme N, Hanson H, Turnbull C, Hume S. Eur J Hum Genet. 2024 Mar 5. doi: | 03/24 | 03/25 | 03/24 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|--|---|---|-------|-------|-------|--|
| | | | 10.1038/s41431-023-01507 PMID: 38443545 | | | | |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risks Giblin J, Coad B, Lamb C, Berlin C, Rea G, Hanson H, Snape K, Berner A; Consensus Meeting attendees. BJC Rep. 2023 Jun 22;1(1):1. doi: 10.1038/s44276-023-00002-0. PMID: 39516684; | 06/22 | 03/25 | 06/22 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) . Hanson H, Astiazaran Symonds, M. Amendola L, Balmaña J, Foulkes W, James P, Klugman S, Ngeow J, Schmutzler R, Voian N, Wick M, Pal T, Tischkowitz M, Stewart D; on behalf of | 10/23 | 03/25 | 10/23 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|--|---|--|-------|-------|-------|--|
| | | | the ACMG Professional Practices and Guidelines Committee. Genet Med. 2023 Oct;25(10):100870. doi: 10.1016/j.gim.2023.100870. PMID: 37490054 | | | | |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F. J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. PMID: 36411 | 11/22 | 03/25 | 11/22 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|---|---|--|-------|-------|---------|--|
| Helen Hanson | Committee member - Clinical Geneticist | Direct-financial | Consultant in Cancer Genetics, Royal Devon University Healthcare NHS Foundation Trust | 09/23 | 03/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Helen Hanson | Committee member - Clinical Geneticist | Direct-financial | Associate Professor Clinical Cancer Genetics, University of Exeter Medical School | 09/23 | 03/25 | Ongoing | Declare and participate Salaried employment |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Christopher J, Edgerley K, McIlldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. J Med Genet. 2025 Oct 1:jmg- 2025-110979. doi: 10.1136/jmg-2025- 110979. Epub ahead of print. PMID: 41159931. | 10/25 | 01/26 | | Non-specific Declare and participate |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Salaried General Practitioner, Rosebank Health Primary Care Network, Gloucester | 2017 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |

| | | | | | | | |
|-------------|---|------------------|--|-------|-------|---------|--|
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Clinical Lead Cancer, NHS Gloucestershire | 2013 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Breast Physician, Gloucestershire Hospitals NHS Foundation Trust | 2022 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Chair Gloucestershire GP Education Trust - this is a membership charitable organisation offering aspirational GP education with local provider colleagues and as Education Programme Director and Honorary Tutor I take an active role in forming policy/ strategy and planning/ facilitating educational events. I kite- mark all GGPET education sessions for quality of GP education. I attend NHS Gloucestershire's monthly HEE Training Hub meetings. | 2013 | 06/25 | Ongoing | Declare and participate Salaried employment in non-profitable organisation |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Gloucestershire LMC Medical Executive I am an appointed salaried officer of the LMC serving | 11/25 | 12/25 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|--------------|--|---|--|-------|-------|---------|--|
| | | | in an non-voting capacity and cannot hold elected officer position on the Gloucestershire Committee. I provide professional support to the Gloucestershire local Committee, dedicate time to LMC matters, and keep the Committee informed of local, regional, and national issues. | | | | |
| Ashley Hurst | Committee member – Lay member | Direct, non-financial professional and personal | Member of NICRCF (Northern Ireland Cancer Research Consumer Forum) | | 06/25 | | Non-specific Declare and participate |
| Ashley Hurst | Committee member – Lay member | Direct, non-financial professional and personal | PPI Member of NiCAN Breast CRG (Northern Ireland Cancer Network Breast Clinical Reference Group). | | 06/25 | | Non-specific Declare and participate |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct-financial | Consultant in Cancer Genetics and Breast Medical Oncology, Royal Marsden Hospital | 12/12 | 03/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct-financial | Private practice at Royal Marsden, 2 hours per week (approximately 6% of my overall practice is private). This includes | 04/21 | 03/25 | Ongoing | Declare and participate Private practice represents 6% of overall practice. |

| | | | | | | | |
|----------|--|---|--|-------|-------|-------|--|
| | | | germline genetic testing primarily for breast cancer patients. | | | | |
| Zoe Kemp | Committee member - Clinical Geneticist | Indirect-financial | I work one day a week on an NHS Transformation programme for genetic testing in breast cancer patients. This research day is with the Institute for Cancer Research and is funded by an SBRI Healthcare grant. Research funding goes to the institute. | 2024 | 03/25 | 03/25 | Specific Declare and participate Open declaration is sufficient mitigation |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct-financial | I gave an educational talk for Pfizer and received honorarium. The presentation was on germline testing for breast cancer patients and which patients were eligible under the National Test Directory. | 2024 | 03/25 | 2024 | Specific Declare and participate Reimbursement is reasonable in return of expertise. |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Attendance at the San Antonio Breast Cancer Symposium 9-12 December 2025. I am not presenting however I am an author on an accepted poster. All expenses to | 12/25 | 11/25 | 12/25 | Non-specific Declare and participate |

| | | | | | | | |
|------------|--|---|---|-------|-------|---------|---|
| | | | attend have been covered personally. | | | | |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. J Med Genet. 2025 Oct 1;jmg-2025-110979. doi: 10.1136/jmg-2025-110979. Epub ahead of print. PMID: 41159931. | 10/25 | 01/26 | | Non-specific Declare and participate |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct-financial | Consultant Genetic Counsellor, Manchester Centre for Genomic Medicine | 08/21 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Woodward ER, Lalloo F, Forde C, Pugh S, Burghel GJ, Schlecht H, Harkness EF, Howell A, Howell SJ, Gandhi A, Evans DG. Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in | 03/24 | 07/25 | | Non-specific Declare and participate |

| | | | | | | | |
|------------|---------------------------------------|---|--|-------|-------|--|---|
| | | | 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400. J Med Genet. 2024 Mar 21;61(4):385-391. doi: 10.1136/jmg-2023-109671 . PMID: 38123987. | | | | |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Evans DG, Burghel GJ, Howell SJ, Pugh S, Forde C, Howell A, Lalloo F, Woodward ER. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2. J Med Genet. 2024 Aug 29;61(9):853-855. doi: 0.1136/jmg2023-109826 . PMID: 38609177; PMCID: PMC11420751 | 08/24 | 07/25 | | Non-specific Declare and participate |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Sodde P, Hyder Z, Pugh S, Lalloo F, Martin R, Soh C, Naqvi J, Whitehouse R, Evans DG, Woodward ER. Evaluation of whole-body MRI for cancer early | 06/25 | 07/25 | | Specific Declare and participate |

| | | | | | | | |
|------------|---------------------------------------|---|---|-------|-------|--|--|
| | | | detection in Li-Fraumeni syndrome. J Med Genet. 2025 Jun 30:jmg-2025-110704. doi: 10.1136/jmg-2025-110704 . Epub ahead of print. PMID: 40588398. | | | | Keep under review based on the topic under consideration. |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Evans DG, Morgan RD, Forde C, Crosbie EJ, Burghel GJ, Pugh S, Gandhi A, Howell A, Howell SJ, Woodward ER, Lalloo F. Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer. J Med Genet. 2025 Nov 19:jmg-2025-110869. doi: 10.1136/jmg-2025-110869 . Epub ahead of print. PMID: 41260924. | 11/25 | 12/25 | | Specific Declare and participate Keep under review while included studies are identified for RQ1 on diagnostic risk tools. |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Member of consensus group / not co-author: Christopher J, Edgerley K, McIlldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary | 10/25 | 12/25 | | Non-specific Declare and participate |

| | | | | | | | |
|-----------------|--------------------------------------|---|--|------|-------|---------|---|
| | | | breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. J Med Genet. 2025 Oct 1:jmg-2025-110979. doi: 10.1136/jmg-2025-110979. Epub ahead of print. PMID: 41159931. | | | | |
| Kathryn Rigby | Committee member – Breast Surgeon | Direct-financial | Consultant Oncoplastic Breast Surgeon – Doncaster & Bassetlaw Teaching Hospitals NHS Trust | 2012 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Kathryn Rigby | Committee member – Breast Surgeon | Non-financial professional and personal | Member of Association of Breast Surgery Clinical Standards and Practice committee, as a regional representative and then communications representative. We review and publish guidance/ information on relevant topics for ABS members, clinical and non-clinical. | 2017 | 06/25 | Ongoing | Non-specific Declare and participate |
| Tamsin Sargeant | Committee member – Lay member | Direct, non-financial professional and personal | I'm a volunteer for Breast Cancer Now and I offer telephone and email support to women around their breast cancer | 2013 | 05/25 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|-----------------|--|------------------|---|-------|-------|---------|---|
| | | | diagnosis, including familial breast cancer. | | | | |
| Hannah Seabrook | Committee member – Clinical Psychologist | Direct-financial | I currently work as a Consultant Clinical Psychologist within the NHS in an Oncology Service that offers risk reducing mastectomy assessments for University Hospitals Coventry and Warwickshire NHS Trust. | 06/18 | 05/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Consultant Clinical Oncologist, Ipswich Hospital | 03/03 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Clinical Director for Oncology and Haematology across East Sussex and North Essex NHS Foundation Trust. Includes Chair of rapid decision group for chemotherapy prescribing in Trust wide electronic patient record and member of multidisciplinary cross-site genomics meeting establishing genetic and genomic testing pathways. | 09/21 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |

| | | | | | | | |
|-------------|---|------------------|---|-------|-------|---------|--|
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Clinical Lead, Oncology | 03/19 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to attend ESMO Breast 2024 | 05/24 | 07/25 | | Specific Declare and participate Attendance at conference. |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis to discuss breast cancer treatment (use of Ribociclib for advanced breast cancer). Not relevant to topic under consideration. | 12/24 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis discussing breast cancer treatment (use of Ribociclib for advanced breast cancer). Not relevant to topic under consideration. | 10/23 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis (use of Ribociclib for advanced breast cancer). Relevant to breast cancer but not topic under consideration. | 08/23 | 07/25 | | Non-specific Declare and participate |

| | | | | | | | |
|-------------|---|------------------|--|-------|-------|-------|---|
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis. Relevant to breast cancer but not topic under consideration. | 02/23 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to attend meeting to discuss breast cancer by Daachi Sanyo. This relates to use of Enhertu for metastatic Her 2 positive breast cancer. | 04/25 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Paid host of Novartis sponsored evening educational meeting discussing role of adjuvant ribociclib. Relevant to breast cancer but not topic under consideration. | 09/25 | 11/25 | 09/25 | Non-specific Declare and participate |